F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comBajaj Healthcare Ltd is a well-established pharmaceutical and nutraceutical manufacturer involved in producing Active Pharmaceutical Ingredients (APIs), formulations, and herbal extracts. Over recent years, the company has grown through product diversification and an expanding global footprint. With improving operational efficiency and rising healthcare demand, Bajaj Healthcare is gaining strong interest from long-term investors.
In this blog, we will evaluate Bajaj Healthcare’s share price targets from 2025 to 2030 based on market valuation, financial outlook, and shareholding strength.
| Detail | Value |
|---|---|
| Open | ₹429.95 |
| Previous Close | ₹426.65 |
| Volume | 957,647 |
| Value (Lacs) | 4,141.34 |
| VWAP | ₹446.14 |
| Beta | 1.14 |
| Market Cap (Rs. Cr.) | 1,365 |
| Day High | ₹458.00 |
| Day Low | ₹429.95 |
| UC Limit | ₹511.95 |
| LC Limit | ₹341.35 |
| 52 Week High | ₹745.00 |
| 52 Week Low | ₹372.35 |
| Face Value | ₹5 |
| All-Time High | ₹745.00 |
| All-Time Low | ₹257.45 |
| 20D Avg Volume | 99,443 |
| 20D Avg Delivery (%) | 46.23 |
| Book Value Per Share | ₹141.16 |
| Dividend Yield | 0.23% |
The stock is trading at a moderate price range compared to its 52-week high. Given the delivery volume and valuation figures, the stock shows potential for future recovery and expansion.
Bajaj Healthcare is engaged in the development and manufacturing of pharmaceutical APIs, intermediates, and nutraceutical products. The company has a strong research and development base and continues expanding into new therapeutic segments.
With increasing global pharma outsourcing, cost-effective Indian manufacturing, and the company’s ability to scale production, Bajaj Healthcare holds long-term growth prospects.
Manufacturer of APIs, formulations & herbal nutraceuticals
Growing product portfolio across major therapeutic segments
Strong R&D capabilities supporting new product launches
Market expansion possible through exports & contract manufacturing
Positioned to benefit from rising demand for healthcare essentials
| Investor Category | Holding (%) |
|---|---|
| Promoters | 59.19% |
| Retail & Others | 36.70% |
| Mutual Funds | 1.66% |
| Other Domestic Institutions | 1.33% |
| Foreign Institutions | 1.12% |
High promoter shareholding indicates confidence in future growth. Retail participation is also significant, showing market trust at investor level.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|
| 2025 | 510 | 585 |
| 2026 | 590 | 680 |
| 2027 | 675 | 770 |
| 2028 | 760 | 875 |
| 2029 | 860 | 995 |
| 2030 | 980 | 1,150 |
Product expansion and improvement in market demand may support gradual price recovery. If margins improve, valuations could strengthen.
Advances in API development and increased formulation exports could drive revenue growth, pushing the stock upward.
With increasing domestic and international medical demand, the company may scale more efficiently, leading to higher price levels.
R&D-driven product launches and contract manufacturing tie-ups may accelerate returns for long-term investors.
If operational expansion succeeds, the share could witness a re-rating supported by global supply demand.
By 2030, the company may establish a stronger export base, diversify across high-margin pharmaceutical categories, and unlock major scale-driven growth.
Bajaj Healthcare has potential for long-term growth driven by pharmaceutical and nutraceutical demand. The current valuation level leaves room for appreciation if revenue and profitability scale consistently. However, investors should track regulatory updates, product approvals, and quarterly earnings before making decisions.
Bajaj Healthcare Ltd is positioned as an expanding pharma business with scalable manufacturing capabilities and a promising product portfolio. If growth continues, the share could reach ₹980–₹1,150 by 2030, making it a potentially rewarding long-term investment for investors looking into the healthcare and pharma sector.
1. What is Bajaj Healthcare’s share price target for 2025?
Expected range is ₹510–₹585.
2. What is the 52-week high of Bajaj Healthcare?
₹745.00.
3. How much promoter holding does the company have?
Promoters hold 59.19%.
4. What is the projected share price target for 2030?
₹980–₹1,150 based on future performance.
5. Is Bajaj Healthcare suitable for long-term investment?
With sector growth and product expansion, it may offer long-term potential.
Disclaimer: This article is for information purposes only. Always analyse carefully or consult an advisor before investing.
Register & Login